Released May 6, 2021, after the close
10-Q filed May 7, 2021, 37 days after period end · 0001564590-21-025155
Q1 2021 · 10-Q
Revenue$14.66M$14.66M +105.0% vs Q1 2020+77.1% vs Q4 2020
Net Income-$30.36M-$30.36M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.66-$0.66 N/M vs Q1 2020N/M vs Q4 2020
Operating Income-$19,009,000N/M
Operating Cash Flow-$30,430,000N/M
Margins · derived
Operating margin-129.7%+138.5 pt vs Q1 2020
Net margin-207.1%+66.9 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $14.66M | $7.15M | $8.63M | $5.79M |
| Net Income | -$30.36M | -$19.60M | -$14.25M | -$12.05M |
| EPS Diluted | -$0.66 | -$0.84 | -$0.62 | -$25.76 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR